Amino-terminal Truncation of Chemokines by CD26/Dipeptidyl-peptidase IV
Article 1998 en
Authors
PP
Paul Proost
IM
Ingrid De Meester
DS
Dominique Schols
Abstract
1 min read
Chemokines are key players in inflammation and infection. Natural forms of the C-X-C chemokine granulocyte chemotactic protein-2 (GCP-2) and the C-C chemokine regulated on activation normal T cell expressed and secreted (RANTES), which miss two NH2-terminal residues, including a Pro in the penultimate position, have been isolated from leukocytes or tumor cells. In chemotaxis and intracellular calcium mobilization assays, the truncation caused a reduction in the specific activity of RANTES but not of GCP-2. The serine protease CD26/dipeptidyl-peptidase IV (CD26/DPP IV) could induce this observed NH2-terminal truncation of GCP-2 and RANTES but not that of the monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. No significant difference in neutrophil activation was detected between intact and CD26/DPP IV-truncated GCP-2. In contrast to intact natural RANTES(1-68), which still chemoattracts monocytes at 10 ng/ml, CD26/DPP IV-truncated RANTES(3-68) was inactive at 300 ng/ml and behaved as a natural chemotaxis inhibitor. Compared with intact RANTES, only a 10-fold higher concentration of RANTES(3-68) induced a significant Ca2+ response. Furthermore, RANTES(3-68) inhibited infection of mononuclear cells by an M-tropic HIV-1 strain 5-fold more efficiently than intact RANTES. Thus, proteolytic processing of RANTES by CD26/DPP IV may constitute an important regulatory mechanism during anti-inflammatory and antiviral responses.
Sofie Struyf, Paul Proost, Dominique Schols, De Clercq Erik, Ghislain Opdenakker, Jean‐Pierre Lenaerts, Michel Detheux, Marc Parmentier, Ingrid De Meester, Simon Scharpé, Jo Van Damme
Paul Proost, Sofie Struyf, Dominique Schols, Ghislain Opdenakker, Silvano Sozzani, Paola Allavena, Alberto Mantovani, Koen Augustyns, Gunther Bal, Achiel Haemers, Anne‐Marie Lambeir, Simon Scharpé, Jo Van Damme, Ingrid De Meester
Discussion(0)
No comments yet. Be the first to comment.